New stock news | Zec Pharmaceuticals (688266.SH) Hong Kong IPO prospectus has become invalid.
Suzhou Zejing Biopharmaceutical Co., Ltd. (referred to as Zejing Pharmaceutical, 688266.SH)s Hong Kong IPO prospectus submitted on December 19, 2025 expires after 6 months on June 19, 2026, with CICC being its exclusive sponsor at the time of submission.
Suzhou Zejing Biopharmaceutical Co., Ltd. (referred to as Zejing Pharmaceuticals, 688266.SH) submitted its Hong Kong IPO prospectus on December 19, 2025, which was valid for 6 months and expired on June 19, 2026. CICC was its exclusive sponsor at the time of submission.
The prospectus shows that Zejing Pharmaceuticals is a comprehensive biopharmaceutical company, focusing on the discovery, research and commercialization of innovative small molecule and biologic therapies, with a strategic focus on oncology, autoimmune diseases, and hemostasis/blood disorders.
Related Articles
Zhou Heiya (01458) spent approximately HK$646,600 to repurchase 512,500 shares on June 22nd.
On June 22, FLAT GLASS (06865) spent 9.9988 million Hong Kong dollars to buy back 1.47 million shares.
GEEKPLUS-W (02590) intends to repurchase company shares.
Zhou Heiya (01458) spent approximately HK$646,600 to repurchase 512,500 shares on June 22nd.
On June 22, FLAT GLASS (06865) spent 9.9988 million Hong Kong dollars to buy back 1.47 million shares.
GEEKPLUS-W (02590) intends to repurchase company shares.
RECOMMEND
